Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Gharbiya, Magda ^a   Iannetti, Ludovico ^b   Parisi, Francesco ^a   De Vico, Umberto ^c   Mungo, Maria Laura ^c   Marenco, Marco ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Istituto di Cura Villa Benedetta   (Italy)

^c Serv Reumatologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CHOROIDAL THICKNESS; CLINICAL ARTICLE; HUMAN; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; RETINA DETACHMENT; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID; THICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESISTANT NEOVASCULAR AGE RELATED MACULAR DEGENERATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; VISION DISORDERS; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84901762313     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/273754     Document Type: Article

References (20)

1. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
2. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
3. Martin D. F., Maguire M. G., Ying G.-S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
4. Martin D. F., Maguire M. G., Fine S. L., Ying G.-S., Jaffe G. J., Grunwald J. E., Toth C., Redford M., Ferris F. L. III, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012 119 7 1388 1398 2-s2.0-84860591842 10.1016/j.ophtha.2012.03.053
5. Binder S., Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? British Journal of Ophthalmology 2012 96 1 1 2 2-s2.0-84455180610 10.1136/bjophthalmol-2011-301236
6. Stewart M. W., Rosenfeld F. J., Predicted biological activity of intravitreal VEGF trap. British Journal of Ophthalmology 2008 92 5 667 668 2-s2.0-43649083100 10.1136/bjo.2007.134874 (Pubitemid 351684178)
7. Heier J. S., Brown D. M., Chong V., Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012 119 12 2537 2548
8. Cho H., Shah C. P., Weber M., Heier J. S., Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. British Journal of Ophthalmology 2013 97 8 1032 1035
9. Bakall B., Folk J. C., Boldt H. C., Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. American Journal of Ophthalmology 2013 156 1 15 22
10. Yonekawa Y., Andreoli C., Miller J. B., Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. American Journal of Ophthalmology 2013 156 1 29 35
11. Heussen F. M., Shao Q., Ouyang Y., Joussen A. M., Müller B., Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2013 10.1007/s00417-013-2553-7
12. Ho V. Y., Yeh S., Olsen T. W., Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. American Journal of Ophthalmology 2013 156 1 23 28
13. Wykoff C. C., Brown D. M., Maldonado M. E., Croft D. E., Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). British Journal of Ophthalmology 2014 10.1136/bjophthalmol-2013-304736
14. Kumar N., Marsiglia M., Mrejen S., Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013 33 8 1605 1612
15. Chang A. A., Li H., Broadhead G. K., Hong T., Schlub T. E., Wijeyakumar W., Zhu M., Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014 121 1 188 192
16. Punjabi O. S., Huang J., Rodriguez L., Lyon A. T., Jampol L. M., Mirza R. G., Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy. British Journal of Ophthalmology 2013 97 8 1024 1031
17. Yamazaki T., Koizumi H., Yamagishi T., Kinoshita S., Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012 199 8 1621 1627 2-s2.0-84860565459 10.1016/j.ophtha.2012.02.022
18. Schraermeyer U., Julien S., Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes. Expert Opinion on Biological Therapy 2013 13 2 156 167
19. Schraermeyer U., Julien S., Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 250 9 1303 1313
20. Julien S., Biesemeier A., Taubitz T., Schraermeyer U., Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. British Journal of Ophthalmology 2014 10.1136/bjophthalmol-2013-304019